The post-Category-2 environment opened a wide consumer-facing information gap that mainstream medical and patient-information outlets are now filling. Compounded peptides exited Category 2 effective April 23, 2026, the FDA's July 23–24 PCAC meeting will set the next regulatory step, and search and telehealth interest in BPC-157, TB-500, GHK-Cu, and the broader peptide category has surged.
Coverage on this site has tracked the wave: the AMA's late-April "What Doctors Wish Patients Knew About Injectable Peptides" primer, AJMC's oral-peptides FAQ on bioavailability and safety, and Hello Peptide's HelloPeptide.net consumer-education platform launch on April 30. They sit alongside earlier safety-skewed pieces from STAT, Scientific American, the Washington Post, ABC News affiliates, and Columbia Doctors. The effect is to mainstream a conversation that was previously confined to clinician forums and biohacker subreddits.
Stories here cover the consumer-education push and the safety messaging that surrounds it. See #patient-safety, #injectable-peptides, and #peptide-policy.
Drexel University's news desk ran a May 5 Q&A on peptide popularity and safety, framed by the FDA's April Category 2 removals and the upcoming July 23–24 PCAC meeting on seven peptides for the 503A bulks list. The piece covers why peptides are surging — easier and cheaper synthesis since the 1980s genetic-engineering era, plus newer molecules like GLP-1 with broad therapeutic effects — and the safety gaps: pharmacy-to-pharmacy compounding variability, supply not keeping up with demand, and a gray-market problem that pushes patients to unverified online sources. The Q&A joins the AMA, AJMC, Pharmacy Times, MIT Technology Review, and the American Council on Science and Health pieces in the post-Category-2 consumer-education ecosystem.
AJMC ran a consumer-grade FAQ on oral peptides covering bioavailability (typically <1% even with optimized formulations), delivery technologies (SNAC for oral semaglutide, liposomal systems, lipidation as in liraglutide and insulin detemir), and the safety distinction between FDA-approved oral peptides and the wave of unverified products. The piece sits alongside the AMA's late-April primer on injectable peptides and STAT, Scientific American, Washington Post, and ABC News coverage from earlier in the year — collectively building the public-facing safety narrative ahead of the July 23–24 PCAC meeting. The FAQ explicitly flags the FDA expert-panel review and the gap between Category 2 removal and FDA approval.
The American Medical Association published a consumer-facing primer on April 30 framing the safety risks of unregulated injectable peptides marketed online for weight loss, recovery, muscle growth, and anti-aging. Physicians quoted in the piece urge patients to push past social-media claims and discuss intended use with a clinician, noting that many products sold under wellness branding are not FDA-approved and may carry sterility, dosing, and interaction risks. The piece joins recent coverage from STAT, Scientific American, the Washington Post, ABC News affiliates, and Columbia Doctors as mainstream medicine reacts to the post-Category-2 environment.
Hello Peptide announced an expansion of its digital platform HelloPeptide.net on April 30, positioning it as a research-aligned consumer education resource for adults navigating GLP-1 and peptide-therapy decisions. The launch is timed to a documented surge in consumer search and telehealth inquiries that followed the FDA's April 22 Category 2 removal of 12 peptides and the upcoming July 23–24 PCAC meeting. The platform sits alongside FormBlends' 2026 State of Peptides report and a wave of legacy-media safety primers as the post-restriction information ecosystem takes shape.